Billing and Coding: Transcranial Magnetic Stimulation (TMS)

TMS is covered for treatment of depressive disorders per the related LCD (L37086) when provided with an FDA‑approved TMS device and documented medical necessity. Initial coverage is up to 20 visits over 4 weeks plus 5 tapering visits, with conditional extensions (10 visits + 6 tapering) for patients with ≥25% improvement and retreatment allowed for prior responders (>50% improvement) who relapse. Maintenance TMS is non‑covered and all treatment must be documented with validated depression rating scales and complete, legible medical records.

"Transcranial magnetic stimulation (TMS) is considered reasonable and necessary for treatment of depressive disorders as described in the related LCD L37086."

Sign up to see full coverage criteria, indications, and limitations.